Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2026)

Barinthus Biotherapeutics filings provide 6 years of Current Deferred Revenue readings, the most recent being $318000.0 for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue fell 78.23% to $318000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $318000.0, a 78.23% decrease, with the full-year FY2025 number at $1.4 million, down 19.68% from a year prior.
  • Current Deferred Revenue hit $318000.0 in Q1 2026 for Barinthus Biotherapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.0 million in Q3 2024 to a low of $111000.0 in Q3 2022.
  • Median Current Deferred Revenue over the past 4 years was $1.4 million (2025), compared with a mean of $1.0 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 81.76% in 2025 and later tumbled 78.23% in 2026.
  • Barinthus Biotherapeutics' Current Deferred Revenue stood at $111000.0 in 2022, then surged by 1465.77% to $1.7 million in 2024, then dropped by 19.68% to $1.4 million in 2025, then tumbled by 77.22% to $318000.0 in 2026.
  • The last three reported values for Current Deferred Revenue were $318000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025) per Business Quant data.